December 11, 2024

New Tests

IDHNow for AML Sponsored Testing Program

We are pleased to announce the IDHNow for AML Sponsored Testing Program. In partnership with Servier, the program provides no-cost testing to eligible patients with acute myeloid leukemia (AML). This testing plays a vital role in assessing prognosis, providing valuable insights to tailor personalized treatment plans.

AML is one of the most common forms of leukemia in adults, representing ~80% of all cases,¹ and up to 16% of patients may harbor an IDH1 mutation.² In fact, 85% of all AML cases have at least one somatic mutation.³

Clinical practice guidelines recommend performing molecular testing to identify IDH mutations in AML patients.⁴ Expedited analysis of biomarkers is crucial for informing treatment decisions and identifying new therapies that could improve patient outcomes.

We invite you to visit us online to learn more.

1. Beaton M, Peterson GJ, O'Brien K. Acute Myeloid Leukemia: Advanced Practice Management From Presentation to Cure. J Adv Pract Oncol. 2020 Nov-Dec;11(8):836-844. doi: 10.6004/jadpro.2020.11.8.4. Epub 2020 Nov 1. PMID: 33489424; PMCID: PMC7810269.
2. Zarnegar-Lumley S, Alonzo TA, Gerbing RB, et al. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Advances. 2023;7(19):5941-5953. doi:10.1182/bloodadvances.2022008282
3. Yu, J., Li, Y., Li, T. et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol 9, 2 (2020). doi.org/10.1186/s40164-019-0158-5
4. Arber DA et al. Arch Pathol Lab Med. 2017;141(10):1342-1393. doi:10.5858/arpa.2016-0504-CP

 

IHC

New Limited Consult Panels – As of Monday, December 9th, NeoGenomics now offers four (4) new Limited Consult Panels. These panels bundle together the necessary IHCs for a specific disease and consolidate them into a limited consult with a TAT of 5 days.

A NeoGenomics pathologist will only order the necessary IHC testing and will evaluate the submitted material within the scope of the specific pathology question selected. Please note that these consults are not intended for subspecialty second opinions or primary diagnostic reports. If a full second opinion consult is required, please order a Full Consultation.

Ordering – The tests are orderable now via online ordering 1.0, 2.0, interface orders and on our paper IHC requisitions available on our website.

• Amyloidosis
  • Includes Congo Red stain, Amyloid A IHC, and Amyloid P IHC
  • CPT codes 88342 x 1, 88341 x 1 and 88313 x 1
• IgG/IgG4
  • For IGG4-related disease, will include IgG/IgG4 IHC; additional studies, CD138, light chains, etc. will be added if needed)
  • CPT codes 88360 x 2
• Carcinoma Micromets
  • Includes Cytokeratin IHC
  • CPT code 88342 x 1
• Melanoma Micromets
  • Includes Melan A, and HMB45 IHC
  • CPT codes 88342 x 1 and 88341 x 1

 

AML MRD Flow Panel

NeoGenomics is proud to announce a new Flow assay for the assessment of Minimal Residual Disease (MRD) in patients with acute myeloid leukemia (AML). AML MRD Flow Panel can be used as a prognostic/predictive assay for risk assessment and treatment decision making and to monitor for relapse. Sensitivity meets or exceeds ELN-defined requirements for flow-based AML MRD testing and supports tailoring of treatment plans that may lead to better patient outcomes.

AML MRD Flow Panel is a 20-biomarker panel containing unique markers that can detect aberrant overexpression in leukemic myeloblasts to complement classic markers recommended by ELN MRD Working Party.

• Markers: CD7, CD11b, CD13, CD14, CD15, CD16, CD19, CD2, CD33, CD34, CD38, CD4, CD45, CD56, CD64, CD65, CD87, CD117, CD371, HLA-DR

Test Details:

• Specimen Requirements: Bone marrow aspirate: 2-3 mL, first pull. EDTA preferred. Sodium heparin tube acceptable.
• Turnaround Time (TAT): 1-2 days
• CPT Codes*: 88184x1, 88185x19. Add 88189x1 for global.
• NYS Approval? No

For more info, please contact your local Territory Business Manager or visit the test menu page here.

 

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

 

Test Update

NRAS Mutation Analysis by PCR

This test is now available for New York state orders as of Monday, December 9th!

This test is a real-time PCR-based assay designed to detect somatic mutations in exons 2, 3 and 4 of the NRAS gene. Please note that the scoring of this test indicates whether any pathogenic NRAS mutation was present, “Detected” or “Not Detected”, but the specific NRAS mutation is not reported. For more test details and specimen requirements, please visit the test menu page.